Novo Nordisk(US:NVO) GLP1减重宝典·2026-01-28 10:35Core Insights - The European Medicines Agency's Committee for Medicinal Products for Human Use has given a positive opinion for the approval of a higher dose of Wegovy (semaglutide 7.2 mg) for obesity treatment, marking a significant advancement in the obesity drug market in Europe [5] - The STEP UP study showed that non-diabetic obese patients treated with semaglutide 7.2 mg for 72 weeks experienced an average weight loss of 20.7%, with about one-third of patients achieving a weight loss of 25% or more, indicating the potential of higher doses for severe weight loss needs [5][6] - The safety and tolerability of semaglutide 7.2 mg are consistent with the already approved 2.4 mg dose, with 84% of weight loss attributed to fat reduction while maintaining muscle function, alleviating concerns about muscle loss during rapid weight loss [6] Clinical Trial Insights - The positive opinion is based on two pivotal Phase III clinical trials: STEP UP and STEP UP T2D, which included obese patients with and without type 2 diabetes, demonstrating the efficacy and safety of the higher dose [7] - The STEP UP trial involved 1,407 non-diabetic obese adults, comparing the weight loss effects of semaglutide 7.2 mg, 2.4 mg, and a placebo over 72 weeks, while the STEP UP T2D trial validated the higher dose's effectiveness in 512 obese patients with type 2 diabetes [7] Regulatory and Market Implications - Novo Nordisk has submitted a marketing application for the semaglutide 7.2 mg single-dose delivery device to the European Medicines Agency, with similar applications under review in the US, UK, and other countries [7] - The advancement of the higher dose Wegovy reflects a shift in the GLP-1 obesity drug competition from mere efficacy to the ability to provide greater and sustainable weight loss, positioning it favorably in the evolving chronic disease management landscape [7]